Articolul precedent |
Articolul urmator |
346 6 |
Ultima descărcare din IBN: 2023-07-04 18:15 |
SM ISO690:2012 AVRICENCO, Mariana, RUSU, Irina, HOLBAN, Tiberiu. Evoluția fibrozei hepatice după tratamentul cu preparate antivirale cu acțiune directă la pacienții cu ciroză hepatică cu VHC. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 312. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | |||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | |||||
|
|||||
Pag. 312-312 | |||||
|
|||||
Descarcă PDF | |||||
Rezumat | |||||
Background. Liver stiffness is a prognostic marker of the evolution of HCV infection. The goal of antiviral therapy in HCV is to obtain a sustained virological response, but also the regression of liver fibrosis. Objective of the study. The objective of this study was to evaluate liver stiffness after treatment with direct-acting antiviral agents in patients with cirrhosis, and to assess the effectiveness of this therapy in these patients. Material and Methods. The prospective, randomized study included 74 patients with HCV and cirrhosis, who received treatment with direct-acting antiviral agents. Patients were divided into two groups: group I - sofosbuvir and daclatasvir / ledipasvir with ribavirin for 12 weeks and group II - sofosbuvir and daclatasvir / ledipasvir for 24 weeks. Results. Distribution of patients: group I - 38 (51.3%) patients, group II - 36 (48.6%). Distribution of patients according to the stage of fibrosis at the initiation of therapy: stage F3 (12.5 - 13.9 kPa) in 4 (5.4%) patients, stage F4 70 (94.5%). At 6 months and 12 months after the end of therapy there was an improvement in liver fibrosis in both groups: in group I the mean value of liver fibrosis at the initiation of antiviral therapy, at 6 and 12 months after treatment was 31 ± 14.0 kPa, 25, 3 ± 10.7kPa and 20.3 ± 10.1kPa; in group II it was 28.5 ± 10.0kPa, 28.2 ± 11.6kPa and 24.3 .1 kPa. Sustained virologic response was - 68 (91.9%) patients, treatment failure - 6 (8.1%). Conclusion. Treatment regimens containing sofosbuvir and daclatasvir / ledipasvir with / without ribavirin have shown promising results and are a good treatment option in cirrhosis with HCV. The results of our study revealed an improvement in liver fibrosis at 6 and 12 months after this therapy. |
|||||
Cuvinte-cheie fibrosis, sofosbuvir, daclatasvir, ledipasvir, ribavirin, fibroză, sofosbuvir, daclatasvir, ledipasvir, Ribavirin |
|||||
|